A Phase I, Open Label, Dose-Escalating Study of the Proteasome Inhibitor PS-341 in Combination With Two Schedules of Herceptin, in Patients With Advanced Breast Cancer That Overexpresses HER-2
Phase of Trial: Phase I
Latest Information Update: 12 Jun 2013
At a glance
- Drugs Bortezomib (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 23 Feb 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 15 Oct 2005 New trial record.